pralmorelin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
growth hormone release-stimulating peptides 2232 158861-67-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pralmorelin
  • pralmorelin hydrochloride
  • GHRP-2
  • pralmorelin dihydrochloride
  • KP-102
  • GHRP
  • KP-102D
  • pralmorelin HCl
  • Molecular weight: 817.99
  • Formula: C45H55N9O6
  • CLOGP: 0.28
  • LIPINSKI: 3
  • HAC: 15
  • HDO: 9
  • TPSA: 256.42
  • ALOGS: -5.72
  • ROTB: 21

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.870 Moderate 0.78
caco2-efflux Caco-2 efflux ratio (BA/AB) 8.054 Moderate 0.78
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.344 10^-6 cm/s Moderate 0.78
dh-clint Dog hepatocyte intrinsic clearance 5.521 uL/min/10^6 cells Moderate 0.78
dppb Dog plasma protein binding (% unbound) 6.510 % Moderate 0.78
fcs-ppb Fetal calf serum protein binding (% unbound) 11.860 % Moderate 0.78
herg hERG pIC50 4.442 pIC50 Moderate 0.78
hh-clint Human hepatocyte intrinsic clearance 62.661 uL/min/10^6 cells Moderate 0.78
hlm-clint Human liver microsomal intrinsic clearance 20.559 uL/min/mg protein Moderate 0.78
hppb Human plasma protein binding (% unbound) 9.980 % Moderate 0.78
kinase-safety-class ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,EPHB4,ERBB2,GRK2,ITK,JAK3,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SIK3,TEK 27
kinase-selectivity-class PDK4 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.784 Moderate 0.78
mh-clint Mouse hepatocyte intrinsic clearance 49.659 Moderate 0.78
mppb Mouse plasma protein binding (% unbound) 3.560 Moderate 0.78
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.864 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 9.400 % Moderate 0.78
rh-clint Rat hepatocyte intrinsic clearance 37.239 uL/min/10^6 cells Moderate 0.78
rh-fuinc Rat hepatocyte fraction unbound in incubation 12.680 % Moderate 0.78
rppb Rat plasma protein binding (% unbound) 2.440 % Moderate 0.78
solubility-dd Solubility at pH 7.4 in DMSO 11.695 uM Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
Oct. 22, 2004 PMDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D006133 Growth Substances

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Growth hormone releasing hormone test indication 252202002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.59 acidic
pKa2 13.08 acidic
pKa3 13.13 acidic
pKa4 13.56 acidic
pKa5 10.31 Basic
pKa6 7.91 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Growth hormone secretagogue receptor type 1 GPCR AGONIST UNKNOWN SCIENTIFIC LITERATURE
Growth hormone secretagogue receptor type 1 GPCR AGONIST Ki 9.30 IUPHAR

External reference:

IDSource
D02040 KEGG_DRUG
C0293969 UMLSCUI
CHEBI:135890 CHEBI
CHEMBL106593 ChEMBL_ID
CHEMBL2105772 ChEMBL_ID
1092 IUPHAR_LIGAND_ID
7604 INN_ID
158827-34-0 SECONDARY_CAS_RN
E6S6E1F19M UNII
6918245 PUBCHEM_CID
1492038 RXNORM
C091874 MESH_SUPPLEMENTAL_RECORD_UI
E6S6E1F19M INXIGHT DRUGS

Pharmaceutical products:

None